Australia Rett Syndrome Drugs Market Analysis

Australia Rett Syndrome Drugs Market Analysis Summary

Australia Rett Syndrome Drugs Market is valued at around $2.7 Mn in 2022 and is projected to reach $6.56 Mn by 2030, exhibiting a CAGR of 11.73% during the forecast period 2023-2030.

Rett syndrome is an uncommon neurological condition that mostly affects women. The disease is characterised by developmental issues, loss of motor skills, and speech impairment. The condition, which is found in children between the ages of 6 and 18 months, is also caused by a mutation in the MECP2 gene on the X chromosome. Rett syndrome can cause a range of problems, from little to major. Rett syndrome is typically characterized by irregular eye movements, slow growth, irritability and agitation, poor language abilities, problems with hand movement, problems with muscular control and coordination, and breathing problems. Despite the fact that Rett syndrome affects many young individuals, many go on to lead happy lives as adults. Since there are only a few recognized treatments for Rett syndrome, the focus of care is on symptom management and improving the quality of life of patients. Occupational, physical, and speech treatments will be helpful for the majority of the affected youngsters. Commonly used drugs for managing symptoms of Rett syndrome are as follows

Antiepileptic medications like valproic acid and clobazam.

Medicines for treating gastrointestinal diseases like laxatives and proton pump inhibitors.

Melatonin and certain sedatives can be used as sleep aids.

Dopamine agonists like bromocriptine or pramipexole improve coordination and movement in individuals.

Nutritional supplements like omega-3 fatty acids improve the overall health and brain function of patients with Rett syndrome.

Trofinetide an oral solution marketed as a daybed for the treatment of Rett syndrome has recently been approved

The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending, and rising global healthcare expenditure. Major global players in Rett Syndrome  Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India).

Market Dynamics

Market Drivers

• ?Increasing prevalence of Rett syndrome

Rett syndrome's rising prevalence will drive industry expansion. The MECP2 gene mutation that causes Rett syndrome. On the long arm of chromosome X, the MECP2 gene produces methyl-CpG binding protein 2. As people grow older, they experience symptoms. Newborns with Rett syndrome grow and develop normally for the first six months before beginning to display symptoms of the condition. Between the ages of 12 and 18 months, typical changes frequently start to occur.

• Increasing infrastructure investment in the healthcare sector

The rising cost of healthcare, which helps to develop its infrastructure, is another important aspect affecting the market's growth rate for Rett syndrome. Even more will be impacted by market dynamics by various government organisations' initiatives to upgrade the healthcare infrastructure by boosting funding.

• The expansion of the market will be accelerated by an increase in the number of government awareness-raising initiatives and a rise in disposable income. The expansion of the female population and higher investments in women's public health programmes are expected to speed up the market.

Market Restraints

It is anticipated that this disease's consequences will impede market expansion. Particular Rett syndrome characteristics can raise a child's risk of getting sick. For instance, difficulties breathing or swallowing may lead to aspiration pneumonia. This kind of pneumonia happens when liquids like food, saliva, or other liquids enter the lungs rather than the stomach. Lung problems are more common among scoliosis sufferers. If you encounter uncontrolled seizures, your chance of getting sick rises. On the other side, the high cost of therapies, diagnostic techniques, and symptomatic therapy will reduce the market's rate of expansion. The market for patients with Rett syndrome would face difficulties due to a lack of competent workers and inadequate healthcare facilities in developing nations. Furthermore, a lack of knowledge and rigorous government rules would slow down and limit the market's growth rate.

Notable deals in Rett Syndrome drugs Market

In March 2023, FDA approved the first drug for the treatment of Rett syndrome which is Trofitenide an oral solution marketed as a daybed.